CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

Nuvalent Inc. (NASDAQ:NUVL) is one of the best 52-week high stocks to buy right now. On November 24, Truist Securities ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:00 AM ESTCompany ParticipantsDavid Hung - Founder, President, ...

Can you get lung cancer without smoking? Yes. A leading oncologist explains the key differences in diagnosis, treatment, and ...

Nuvation Bio stock is downgraded as price reflects Ibtrozi’s strong launch. Get insights on NUVB stock's forward revenue and investor strategies.

A 46-year-old man with advanced lung cancer recovered after doctors used Next Generation Sequencing to identify a rare ALK fusion mutation and treat him with targeted therapy instead of chemotherapy.

Abstract: This research covers the implementation of SLAM (Simultaneous Localization and Mapping) with Ouster OS0 LiDAR (Light Detection and Ranging) sensor in the Robot Operating System (ROS1) Noetic ...

Solihull mum-of-one Catherine Paul felt her body had 'betrayed' her after a cancer diagnosis - despite an organic diet and regular exercise ...

(RTTNews) - Nuvalent Inc. (NUVL) announced that its New Drug Application seeking approval of Zidesamtinib for treating adult patients with advanced ROS1-positive non-small cell lung cancer has been ...

The stake reduction represents a complete exit from Nuvalent, removing an allocation that was previously 13.8% of the fund’s reportable AUM in the prior quarter. Nuvalent is no longer in the portfolio ...

Nuvation Bio ( (NUVB)) has provided an update. On November 8, 2025, Nuvation Bio announced positive results from a Phase 2 study of safusidenib in Japanese patients with IDH1-mutant gliomas, showing a ...